IP Library › Granted Patent US 11,325,924
Granted Patent B2
US 11,325,924 · App. 16/941,821 · Granted May 10, 2022

Modulators of Sestrin-GATOR2 interaction and uses thereof

Inventors: Kristina Michelle Fetalvero (Boston, MA); Sridhar Narayan (Belmont, MA); David John O'Neill (Arlington, MA); Eddine Saiah (Brookline, MA); Shomit Sengupta (Belmont, MA)
Assignee: NAVITOR PHARMACEUTICALS, INC.
C07F7/081A61K31/197A61K31/198A61K31/221A61K31/223A61K31/275A61K31/341A61K31/41A61K31/695A61K38/00A61K45/06C07C229/12C07C229/14C07C229/18C07C229/20C07C229/28C07C233/07C07C233/40C07C233/47C07C233/49C07C233/51C07C233/63C07C233/83C07C237/06C07C237/12C07C237/30C07C255/61C07C261/04C07C311/06C07C311/10C07C311/13C07C311/14C07C311/19C07C311/51C07D257/04C07D307/33C07C2601/04C07C2601/08C07C2601/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,325,924
App. No.
16/941,821
Granted
May 10, 2022
Kind
B2
Abstract

The present invention provides compounds, compositions thereof, and methods of using the same.

Claims (16)

1. A method of treating Huntington's disease in a patient in need thereof, comprising the step of administering a compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is hydrogen;

R 2 is hydrogen;

R 3 is —C(O)OH;

L is

R 4 is —CF 3 , —CH 2 F, —CHF 2 , —CH 2 CHF 2 , —CH 2 CF 3 , or —CH 2 CH 2 CHF 2 ; and

R 5 is hydrogen.

2. The method of claim 1 , wherein said compound is selected from any one of:

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein said compound is selected from:

or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein said compound or pharmaceutically acceptable salt thereof is administered as a pharmaceutically acceptable composition comprising a pharmaceutically acceptable carrier, adjuvant, or vehicle.

5. A method of treating Huntington's disease in a patient in need thereof, comprising the step of administering a compound selected from:

or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 , wherein said compound or pharmaceutically acceptable salt thereof is administered as a pharmaceutically acceptable composition comprising a pharmaceutically acceptable carrier, adjuvant, or vehicle.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2026
From: NAVITOR PHARMACEUTICALS, INC.
To: SUPERNUS PHARMACEUTICALS, INC.
Reel/Frame 075552/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2020
From: FETALVERO, KRISTINA MICHELLE; NARAYAN, SRIDHAR; O'NEILL, DAVID JOHN; SAIAH, EDDINE; SENGUPTA, SHOMIT
To: NAVITOR PHARMACEUTICALS, INC.
Reel/Frame 053340/0859 →
Continuity (6)
Continuation 16515788 · Jul 18, 2019
Continuation 15974734 · May 9, 2018
Continuation 15331362 · Oct 21, 2016
Provisional Application 62336219 · May 13, 2016
Provisional Application 62245553 · Oct 23, 2015
Related Publication 20210047347A1 · Feb 18, 2021
Cited By (4)
US 12,252,456 US 12,378,263 US 12,427,130 US 12,465,583